ABTI Alpha-Beta Technology Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABTI Alpha-Beta Technology

ABTI 0.200

+99,900.0%

Jun 17 12:34 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (326)	7/29/1997 4:37:00 PM
From: gaddis	of 572

Cacaito, I think you need to look at the actual results of the Phase 2 trials before making such assertions. Relying on second-hand information is not a legitimate way of doing research. ABTI did, in fact, demonstrate statistically significant results in reducing serious and/or life-threatening infections. Out of 32 patients receiving 0.5 - 2.0 mg/kg doses, there was one serious infection. Compare this to 8 surgical site infections in 7 patients (out of 32) that received placebo + 0.1 mg/kg of PGG glucan. This yielded a P value of .023 in # of infected patients and .01 in # of surgical site infections.(P<.05 was considered statistically significant). Their rationale for the grouping stemmed from the results of the previous single-center study and pre-clinical trials that demonstrated PGG-glucan to be effective at 0.5 mg/kg or greater. A blinded post-hoc analysis of serious infections (infections that resulted in prolonged hospitalization in the judgment of the investigator) revealed a "prominent effect in reducing such infections". If you would like, I can fax you a reprint of the results.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next